What Should Doctors Know About FDA’s Black Box Change for Hormone Replacement Therapy Drugs? - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

What Should Doctors Know About FDA’s Black Box Change for Hormone Replacement Therapy Drugs?

A Keck Medicine of USC breast surgeon discusses the FDA’s decision — and whether using HRT to treat menopause symptoms actually affects breast cancer risk.

  • January 28, 2026

  • 8 min

Share

Clinical Scorecard: What Should Doctors Know About FDA’s Black Box Change for Hormone Replacement Therapy Drugs?

At a Glance

CategoryDetail
ConditionHormone Replacement Therapy (HRT) for menopause symptoms
Key MechanismsManagement of menopause symptoms such as hot flashes, night sweats, and genitourinary syndrome.
Target PopulationWomen experiencing menopause symptoms.
Care SettingPrimary care and specialized women's health clinics.

Key Highlights

  • FDA removed the black box warning on HRT, potentially increasing its use.
  • HRT is linked to reduced all-cause mortality and other health benefits when started before age 60.
  • Topical HRT does not increase breast cancer risk, unlike systemic HRT.
  • Individual assessment of risks and benefits is crucial for HRT prescription.
  • New research suggests a nuanced understanding of breast cancer risk associated with HRT.

Guideline-Based Recommendations

Diagnosis

  • Reevaluate biases regarding HRT and menopause treatments.
  • Consider individual patient history and symptoms before prescribing HRT.

Management

  • Use HRT responsibly, considering each patient's unique situation.
  • Assess breast cancer risk and recommend appropriate screenings based on individual risk.

Monitoring & Follow-up

  • Monitor breast density changes in patients on HRT.
  • Regularly evaluate the effectiveness and safety of HRT in managing menopause symptoms.

Risks

  • HRT may increase breast density, which can elevate breast cancer risk.
  • Avoid HRT in women with a history of hormone-sensitive invasive breast cancer.

Patient & Prescribing Data

Women experiencing menopause symptoms, particularly those with varying breast cancer risks.

HRT can be beneficial for managing menopause symptoms but requires careful consideration of individual health risks.

Clinical Best Practices

  • Engage in open conversations about menopause and HRT with patients.
  • Stay updated on the latest research regarding HRT and its implications for women's health.
  • Avoid a one-size-fits-all approach; tailor HRT decisions to individual patient needs.

Related Resources & Content

Original Source(s)

What Should Doctors Know About FDA’s Black Box Change for Hormone Replacement Therapy Drugs?

  • January 28, 2026

Related Content

Old disease, new twist

Aortic Dissection at 25: Recognizing a Life-Threatening Emergency in a Young Athlete

An aortic dissection occurs when a tear develops in the inner layer of the aorta, the body’s largest artery. Blood can force its way between layers of the vessel wall, compromising circulation to vital organs or causing catastrophic internal bleeding.

  • by

  • September 22, 2026

  • 7 min
Female patients less likely to receive invasive care

Review identifies recurring sex-based differences across specialties, including lower use of intensive and guideline-compliant treatment among female patients.